ENTXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs...

Stats
本日の出来高	118 877
平均出来高	233 156
時価総額	70.25M
EPS	$0 ( 2024-03-29 )
次の収益日	( $-0.0600 ) 2024-05-03
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.39
ATR14	$0.00800 (0.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Yaacov-garbeli Dana	Buy	130 000	Stock Option (right to buy)
2024-04-19	Yaacov-garbeli Dana	Buy	30 151	Ordinary Shares, par value NIS 0.0000769 per share
2024-04-19	Galitzer Hillel	Buy	130 000	Stock Option (right to buy)
2024-04-19	Galitzer Hillel	Buy	30 151	Ordinary Shares, par value NIS 0.0000769 per share
2024-01-12	Taitel Haya	Buy	9 500	Ordinary Shares, par value NIS 0.0000769 per share

INSIDER POWER
100.00
Last 93 transactions
Buy: 4 653 836 \| Sell: 4 161 674

ボリューム相関

長: -0.58 (weak negative)

短: 0.93 (very strong)

Signal:(56.608) Expect same movement, but be aware

Entera Bio Ltd 相関

10 最も正の相関
TITN	0.854
TBLA	0.849
OPNT	0.84
OFIX	0.838
NAVI	0.835
LCAA	0.834
ATEC	0.831
ALSA	0.828
WDAY	0.827
GLLI	0.825

10 最も負の相関
AVO	-0.847
BLIN	-0.845
GETVV	-0.84
GLUE	-0.839
SIDU	-0.837
ATAI	-0.824
BIMI	-0.819
CEG	-0.816
DRUG	-0.814
GPOR	-0.813

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Entera Bio Ltd 相関 - 通貨/商品

0.10
( neutral )

0.09
( neutral )

0.00
( neutral )

0.55
( weak )

-0.13
( neutral )

Entera Bio Ltd 財務諸表

Annual	2023
収益:	$0
総利益:	$-56 000.00 (0.00 %)
EPS:	$-0.310

FY	2023
収益:	$0
総利益:	$-56 000.00 (0.00 %)
EPS:	$-0.310

FY	2022
収益:	$134 000
総利益:	$33 000.00 (24.63 %)
EPS:	$-0.450

FY	2021
収益:	$571 000
総利益:	$198 000 (34.68 %)
EPS:	$0.425

Financial Reports:

No articles found.

Entera Bio Ltd

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

リアルタイムの更新： Entera Bio Ltd [ENTX]

Upcoming Earnings Alert